Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
Voya Financial CEO Heather Lavallee marks 10 years of Voya Cares, spotlighting research and expanding financial access for Americans with disabilities.
When Treasury Secretary Scott Bessent (above) and Fed chair Jay Powell jointly summon America’s top bankers to a meeting in Washington, you know it’s big.
Kim Crawford Goodman, CEO of Smarsh, breaks down how financial firms are scaling AI while managing compliance, risk, and regulation in a changing landscape.
Elizabeth Renter, Senior Economist at NerdWallet, breaks down how inflation and oil price shocks are driving higher costs and squeezing consumers today.
David Branch of Wells Fargo explains why cocoa prices are falling but some candy costs remain high and when consumers may finally see relief at checkout.
Colonel Chris Hadfield, astronaut and best-selling author, breaks down Artemis II and why NASA’s next crewed mission is key to returning humans to the Moon.
